Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is this reiteration to keep the stock price up over a buck in lieu of buying more shares?
Thanks for posting. Isn’t this just a rehash of what they said 10 or so days ago?
I am also hoping that the MarketEdge piece that ORBAPU posted plays out. Buying stopped after we went touched 1.30 and profit taking ensued for a number of days after. It is now oversold, the momo guys have taken their profits, and this is ready to climb all by itself (well not by itself but without necessarily the need for Denner's gang to get involved). So hoping that by Tuesday night we are well above the 1 buck mark.
Thanks for posting. I think we should stick Nissen's nose in this:
"First of all, we did a responder analysis of the trial patients in the placebo arm looking at those who increased CRP or LDL cholesterol or both compared to those who did not, and it's very striking that their events are the same. That does not seem to account for direct harm in the placebo patients from mineral oil."
AND have him issue a retraction of his prior statements and an apology.
Your post makes me wonder about RWE for V wrt CVD. Surely the insurers must have that. Or is there anything in HIPPA that precludes looking at that?
Ah, that makes sense. I guess too early for my brain to click in.
Gouging. And, I doubt the Generic companies are now charging Cigna 10 times more for the drug.
JRoon, I am wondering if anyone has any idea what the split is between cardios prescribing V versus primary care physicians prescribing V?
I saw this quote from Dr. Bhatt back in 2019 where he thought that specialized docs would start prescribing but that eventually we would see primary care physicians writing. I got mine from my primary care doc.
""Now, the key challenge is to identify and treat appropriate patients," Bhatt noted. He says this task will largely fall on cardiologists, endocrinologists, and primary care physicians, though stroke neurologists, nephrologists, and vascular medicine specialists will also have patients for whom the data are relevant.
"I believe the drug will ultimately be widely prescribed, initially by subspecialists, but by primary care physicians also. It is overall very well tolerated, safe, and easy to use," he said. "Much like statin prescription started in subspecialty practices but then became quite common in primary care, I envision the same happening with icosapent ethyl."
https://www.medscape.com/viewarticle/922865?form=fpf
Wow, that's highway robbery for the GV. They are making a killing - assuming they have a good amount of insured taking the stuff.
Also, are you sure about the 90? All the V and GV I have seen come in bottles of 120.
Yep, I share your thoughts on this. And, JT's gambit might have worked out, but we will never know since the DuDisaster upended the whole thing.
A shame that if JT thought so much of V and Amarin that he didn't protect it better.
It has been shown that the vast majority of small bios selling to BP happens right around phase 3 results. Some before and some just after. Most small bios muck up launches, and the smart ones don’t want to take that chance if they are interested in being bought.
Now, to be fair, we can’t say that Amarin botched their launch because for the first 3 months after label expansion, scripts seemed to be rising quite well. Where they screwed up was not taking care to protect their only product and business from the DuDisaster, if they had wanted to continue GIA until they got a suitable offer.
I also wanted to add concerning the STRENGTH trial results that the article mentioned. It raised a question in my mind. If the results of STRENGTH were positive, (which of course they weren't) would that have meant that it would have made BP more interested in Amarin or less interested because it would mean a bunch more competition. Negative results - would they assume that that meant that R-I was fluke, or should they not think that it meant that V would have no competition from mixed omegas?
I assume because both statins and icosapent ethyl are available as generics here in the States. Of course the EU is different and may be quite applicable to what you posit.
Their stock has been hammered the last couple of years (as I well know with it in my divvy account), so they have to start thinking about placating the investment community and do something different.
This discussion popped two thoughts into my head.
First, the extension of life by some drugs (here we are talking V and CVD) for some of those being treated (yes no drug helps 100% of those treated) might mean an increased longevity which would then mean those subjects contracting some other condition (thinking things like AD, cancer, etc.) costing more money than just dropping dead from a HA.
Secondly, I'm not sure we can ever eradicate all conditions and hence extend life indefinitely. There is not a single species I am aware of that has never died. It is basically the definition of life. Species are most viable (strength, can't find the words I'm looking for) around the time they are able to procreate. After that it is downhill. Most of this is of course buried in DNA replication (errors build up over time) and telomere shortening, and a whole bunch of biology that I can't really understand, but suffice to say that something is going to get us someday.
Damn you!!! Actually, pretty fortunate. Whenever I buy a stock it sinks like a rock.
I guess the EU thinks differently.
Trials demonstrate that Lovaza raises LDL cholesterol anywhere from 10 to 46%. It should be used for short term purposes of reducing extremely high trig levels and not for CVD risk reduction. Of course that is a little too complicated to think about for doctors and the AHA.
I think you are vying for the most truthful post of the day.
Thanks for posting GG. A couple of thoughts popped out.
One, it made me wonder about shareholder approval for the share repurchase program. I can only think of one reason why shareholders would vote against such, namely if they thought it would endanger the business by foolishly wasting needed cash that might be needed for operations or more valuable acquisitions. I really see no way that this doesn't pass easily.
Secondly, I know that an authorized generic has been mentioned in the past, but Holt used the word "compelling" in describing the possibility. Sounds like we might be hearing more about this in the near future. I am guessing if they find it difficult to hold the 57% market share.
Please accept my deepest sympathies. I know you guys recently moved as well and then to have this. Take care of yourself.
Absolutely. And one of the reasons this takes time, is that they first had to stop the bleeding from the previous admin before moving positively in the right direction.
If I may, I suggest you get her a Tomahawk Ribeye now.
Well, I see it is up another 5 cents in premarket (we know premarket can be useless or head fake). I wonder if the ARDX news yesterday buoyed UNCY a bit.
From what I understand the drug binds up phosphate to about the same degree as lanthanum carbonate but only takes up 1/4 of the volume hence making it easier for users (swallowing or less pills). If successful, they will still have a bit of an uphill road to squeeze into the market but with a market cap of only 32 m, and an indication that is quite large, they don't have to have much penetration to see their market cap quintuple at least.
Along with what Whalatane posted, it has been virtually 6 months since SR started. If this is to be sold, six months should be plenty.
No truer words have ever been spoken.
Capt., I notice that you posted on ST about whether one would prefer taking a weight loss drug with some CVD benefits or a CVD drug with weight loss benefits (V).
Not sure if anyone saw the story the other day where the FDA is investigating some of those drugs for potentially dangerous side effects:
https://www.fiercepharma.com/pharma/novo-nordisk-and-eli-lilly-weight-loss-drugs-under-fda-scrutiny-suicidal-thoughts-hair-loss#:~:text=Novo%20Nordisk%2C%20Eli%20Lilly%27s%20weight,for%20suicidal%20thoughts%2C%20hair%20loss&text=Use%20of%20Novo%20Nordisk%20and,which%20can%20be%20life%20threatening.
Seems to be waking up a bit now. Of course the overall market has turned up so that could be pulling it up as well. Waiting for that next rumor.
So far market taking this news and yawning.
But that is what these primary and secondary outcomes were about:
"The proposed study aims to: 1) investigate the effects of 18 months of IPE vs. placebo on regional cerebral blood flow as measured by arterial spin-labeling MRI; 2) determine the impact of 18 months of IPE vs. placebo on CSF biomarkers of AD pathology; and 3) evaluate the effects of 18 months of IPE vs. placebo on cognitive performance."
I think Sleven is a great contributor to this board but I did not agree with his steadfast opinion, that if "successful" BRAVE could lead to V's approval to treat AD. This trial was too small, too short, used healthy subjects with no sign of AD, and whose stated goal was to find out if the drug should be further studied in larger studies.
For me, V has been proven (and backed up by other studies) in a huge study (R-I) for a huge indication and I believe it is that indication that offers our best hope as investors to get out of this investing quagmire with at least the shirts on our backs. Obviously the US market is not going to be where Amarin has to mine the treasure but rather the EU. Unfortunately it has been a slow process but hopefully like a snowball rolling down a mountain, EU scripts gain traction and with that demonstrate to other EU countries on the fence to join in. Then Denner can attempt to package the company to some Eurocentric BP, and make most of us whole.
No question Canam. Denner pays for his shares whereas the prior group had their hands out for free shares.
Yes, I agree that the patients were too healthy and the study duration too short, but, this was primarily a biomarker study so maybe those facets not that important as it is not an outcome study.
Well, it could be, but that would not be what the shares are “worth”.
Thanks for posting. I hope my further observations are not an indication that I still suffering the after effects of last night's imbibing.
But, something seems off with the math:
"Sarissa Capital Management LP now owns 4,910,000 shares of the biopharmaceutical company's stock worth $7,365,000"
"Clearbridge Investments LLC now owns 4,789,575 shares of the biopharmaceutical company's stock worth $15,758,000"
So how could Clearbridge's lesser amount of shares be worth double of Sarissa's?
Yeah, but not the part about dementia, as that would be a boost for Lovaza.
Thanks a ton Kiwi. Happy, Healthy, and Prosperous New Year to you and yours.
Thanks a ton Kiwi. Happy, Healthy, and Prosperous New Year to you and yours.
Yep. 9 out of 10 stocks on my screen did the same dump. Not Amarin related
Read somewhere (could have been on a Yahoo board) where someone claimed that the CEO has stated he has no intention to rollout the drug after approval but rather sell the company. Do you know if that is true? And does Spectrum Pharma hold the patent for oxylantham carbonate?
Orbapu, there is much that I have in common with Kiwi and share many of his views. But on this, you are correct.
Of course Kaiser does not want Kiwi to just die, they keep making money off Uncle Sam with him being in the system. I have read that originally some
had intentions to make Medicare for everyone but the insurance companies fought it tooth and nail and then gladly gave over the 65 and over crowd
since they rack up the most medical costs. Recently they have figured out how to weasel into the Medicare coffers with these MA plans. We all remember
Scott and Columbia HCA.
I guess I was not clear that my use of the word “here” was not referring to the US but to this investment. The EU and ROW for the CVD indication should be enough to yield enough value to make me happy.